Patients/Clinicians

Zelos is developing an innovative portfolio of complementary bone disease therapies covering osteoporosis, fracture repair, multiple myeloma, stem cell transplantation and renal bone disease. A focus on bone and bone marrow diseases allows us to efficiently leverage our expertise to rapidly advance bone formation agents – specifically PTH analogs -  through development for each indication.
 
For more information on Zelos’ clinical trials, please visit:
 
www.clinicaltrials.gov

To review published scientific papers on Zelos' technology, click here.